What is Lithium?
Lithium is used to treat mania that is part of bipolar disorder (manic-depressive illness). It is also used on a daily basis to reduce the frequency and severity of manic episodes. Manic-depressive patients experience severe mood changes, ranging from an excited or manic state (e.g., unusual anger or irritability or a false sense of well-being) to depression or sadness.
It is not known how Lithium works to stabilize a person's mood. However, it does act on the central nervous system. It helps you to have more control over your emotions and helps you cope better with the problems of living.
It is important that you and your family understand all the effects of Lithium. These effects depend on your individual condition and response and the amount of Lithium you use. You also must know when to contact your doctor if there are problems with using the medicine.
Lithium is available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, Lithium is used in certain patients with the following medical conditions:
- Cluster headaches.
- Mental depression.
- Neutropenia (a blood condition where there is a decreased number of a certain type of white blood cells).
Lithium indications
Oral
Bipolar disorder, Mania, Recurrent unipolar depression
Adult: Dose depends on the preparation used. Doses should be adjusted to produce a serum-Lithium concentration of 0.4-1 mmol/l. Camcolit® tablets: Treatment: Initiate at 1-1.5 g daily; Prevention: Initiate at 300-400 mg daily. Priadel® tablets: Treatment and prevention: Initially, 400-1,200 mg daily in 1-2 divided doses. Priadel® syrup: Treatment and prevention: Initially, 1.04-3.12 g daily in 2 divided doses. Liskonum® tablets: Treatment: Initially, 450-675 mg bid; Prevention: Initially, 450 mg bid. Doses should be divided throughout the day during the initial period; once-daily dosing may be used when serum-Lithium concentrations have stabilised. Adjust initial dose 4-7 days after starting based on results of serum-Lithium concentrations. Monitor serum-Lithium concentrations once wkly until dosage has remained constant for 4 wk, after which monitoring may be reduced to once every 3 mth.
Child: ≥12 yr: Acute phase: Serum concentrations of 1-1.2 mEq/l. Max dose: 1.5 mEq/l. Initially, 1.8 g Lithium daily as conventional capsules/tablets in 3-4 divided doses, or 30 ml (approx 48 mEq) Lithium citrate oral solution daily in 3-4 divided doses. Alternatively, initially 1.8 g Lithium daily as extended-release tablets in 2-3 divided doses.
Maintenance: Not established.
Elderly: ≤900 mg Lithium daily. Titrate dose slowly to achieve therapeutic serum concentrations.
Maintenance: Maintain serum concentrations at the lower end of 0.6-1.2 mEq/l.
How should I use Lithium?
Use Lithium as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Lithium by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.
- Drinking extra fluids while you are taking Lithium is recommended. Check with your doctor for instructions.
- Do not change your diet, including the amount of salt in your diet, unless instructed by your doctor.
- If you miss a dose of Lithium, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Lithium.
Uses of Lithium in details
Use: Labeled Indications
Bipolar disorder:
Immediate release: Treatment of manic and mixed episodes and maintenance treatment in patients ≥7 years of age with a diagnosis of bipolar disorder.
Extended release: Treatment of manic episodes and maintenance treatment in patients ≥12 years of age with a diagnosis of bipolar disorder.
Off Label Uses
Bipolar disorder, hypomania
Data from a limited number of patients studied suggest that Lithium may be beneficial in the treatment of hypomania.
Lithium description
Lithium was used during the 19th century to treat gout. Lithium salts such as Lithium (Li2CO3), Lithium citrate, and Lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the Lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.
Lithium dosage
Acute Mania
Optimal patient response to Lithium usually can be established and maintained with 600 mg t.i.d. Optimal patient response to Lithium
Oral Solution usually can be established and maintained with 10 mL (2 full teaspoons) (16 mEq of Lithium) t.i.d. Such doses will normally produce an effective serum Lithium level ranging between 1.0 and 1.5 mEq/l. Dosage must be individualized according to serum levels and clinical response. Regular monitoring of the patient’s clinical state and of serum Lithium levels is necessary. Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.
Long-Term Control
The desirable serum Lithium levels are 0.6 to 1.2 mEq/l. Dosage will vary from one individual to another, but usually 300 mg of Lithium t.i.d. or q.i.d., or 5 mL (1 full teaspoon) (8 mEq of Lithium) of Lithium
Oral Solution t.i.d. or q.i.d. will maintain this level. Serum Lithium levels in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months.
Patients abnormally sensitive to Lithium may exhibit toxic signs at serum levels of 1.0 to 1.5 mEq/l. Elderly patients often respond to reduced dosage, and may exhibit signs of toxicity at serum levels ordinarily tolerated by other patients.
N.B.
Blood samples for serum Lithium determination should be drawn immediately prior to the next dose when Lithium concentrations are relatively stable (i.e., 8-12 hours after the previous dose). Total reliance must not be placed on serum levels alone. Accurate patient evaluation requires both clinical and laboratory analysis.
Lithium interactions
See also:
What other drugs will affect Lithium?
Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Amphetamines: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Angiotensin II Receptor Blockers: May increase the serum concentration of Lithium. Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist. Consider therapy modification
Angiotensin-Converting Enzyme Inhibitors: May increase the serum concentration of Lithium. Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor. Monitor patient response to Lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment. Consider therapy modification
Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Exceptions: Alosetron; Ondansetron; Ramosetron. Monitor therapy
Antipsychotic Agents: Lithium may enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine. Monitor therapy
BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Caffeine and Caffeine Containing Products: May decrease the serum concentration of Lithium. Monitor therapy
Calcitonin: May decrease the serum concentration of Lithium. Monitor therapy
Calcium Channel Blockers (Nondihydropyridine): May enhance the neurotoxic effect of Lithium. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Lithium. Decreased or unaltered Lithium concentrations have also been reported with this combination. Exceptions: Bepridil. Monitor therapy
Calcium Polystyrene Sulfonate: May decrease the serum concentration of Lithium. Management: Consider separating administration of Lithium from administration of oral calcium polystyrene sulfonate by at least 6 hours. Consider therapy modification
CarBAMazepine: May enhance the adverse/toxic effect of Lithium. Monitor therapy
Carbonic Anhydrase Inhibitors: May decrease the serum concentration of Lithium. Exceptions: Brinzolamide; Dorzolamide. Monitor therapy
Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated. Avoid combination
Desmopressin: Lithium may diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium. Monitor therapy
Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Dextromethorphan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Eplerenone: May increase the serum concentration of Lithium. Monitor therapy
Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Exceptions: Nicergoline. Monitor therapy
Fexinidazole [INT]: Lithium may enhance the QTc-prolonging effect of Fexinidazole [INT]. Avoid combination
Fosphenytoin: May enhance the adverse/toxic effect of Lithium. Monitor therapy
Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. Monitor therapy
Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Linezolid: May enhance the serotonergic effect of Lithium. This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes). Consider therapy modification
Loop Diuretics: May decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium. Monitor therapy
Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Methyldopa: May enhance the adverse/toxic effect of Lithium. This may occur without notable changes in serum Lithium concentrations. Monitor therapy
Methylene Blue: May enhance the serotonergic effect of Lithium. This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes). Consider therapy modification
MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Lithium. MetroNIDAZOLE (Systemic) may increase the serum concentration of Lithium. Monitor therapy
Monoamine Oxidase Inhibitors (Antidepressant): May enhance the serotonergic effect of Lithium. This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes). Consider therapy modification
Monoamine Oxidase Inhibitors (Type B): May enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome. Avoid combination
Nefazodone: May enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Neuromuscular-Blocking Agents: Lithium may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Monitor therapy
Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Lithium. Management: Consider reducing the Lithium dose when initiating a NSAID. Monitor for increased Lithium therapeutic/toxic effects if a NSAID is initiated/dose increased, or decreased effects if a NSAID is discontinued/dose decreased. Exceptions: Sulindac. Consider therapy modification
Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Opioid Agonists: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Exceptions: FentaNYL; Meperidine; TraMADol. Monitor therapy
Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk). Management: Concomitant use of ozanimod with serotonergic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification
Phenytoin: May enhance the adverse/toxic effect of Lithium. Monitor therapy
Potassium Iodate: Lithium may enhance the hypothyroid effect of Potassium Iodate. Monitor therapy
Potassium Iodide: May enhance the hypothyroid effect of Lithium. Monitor therapy
QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Monitor therapy
Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Sargramostim: May enhance the adverse/toxic effect of Lithium. Specifically, the myeloproliferative effects may be increased. Monitor therapy
Selective Serotonin Reuptake Inhibitors: Serotonergic Agents (High Risk, Miscellaneous) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Exceptions: Dapoxetine. Monitor therapy
Serotonergic Non-Opioid CNS Depressants: Serotonergic Agents (High Risk, Miscellaneous) may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Serotonergic Opioids (High Risk): May enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined. Monitor therapy
Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Exceptions: Almotriptan; Eletriptan. Monitor therapy
Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Sodium Bicarbonate: May increase the excretion of Lithium. Monitor therapy
Sodium Chloride: May increase the excretion of Lithium. Monitor therapy
Sodium Polystyrene Sulfonate: May decrease the serum concentration of Lithium. Management: Consider separating administration of Lithium from administration of oral sodium polystyrene sulfonate by at least 6 hours. Consider therapy modification
St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Tetracyclines: May increase the serum concentration of Lithium. Monitor therapy
Theophylline Derivatives: May decrease the serum concentration of Lithium. Monitor therapy
Thiazide and Thiazide-Like Diuretics: May decrease the excretion of Lithium. Management: Condsider reducing the Lithium dose by 50% upon initiation of a thiazide diuretic. Monitor for increased Lithium therapeutic/toxic effects if a thiazide is initiated/dose increased, or decreased effects if a thiazide is discontinued/dose decreased. Consider therapy modification
Topiramate: May increase the serum concentration of Lithium. Monitor therapy
Tricyclic Antidepressants: May enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Tryptophan: Lithium may enhance the serotonergic effect of Tryptophan. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Monitor therapy
Lithium side effects
See also:
What are the possible side effects of Lithium?
Lithium Toxicity
The likelihood of toxicity increases with increasing serum Lithium levels. Serum Lithium levels greater than 1.5 mEq/L carry a greater risk than lower levels. However, patients sensitive to Lithium may exhibit toxic signs at serum levels below 1.5 mEq/L.
Diarrhea, vomiting, drowsiness, muscular weakness and lack of coordination may be early signs of Lithium toxicity, and can occur at Lithium levels below 2.0 mEq/L. At higher levels, giddiness, ataxia, blurred vision, tinnitus and a large output of dilute urine may be seen. Serum Lithium levels above 3.0 mEq/L may produce a complex clinical picture involving multiple organs and organ systems. Serum Lithium levels should not be permitted to exceed 2.0 mEq/L during the acute treatment phase.
Fine hand tremor, polyuria and mild thirst may occur during initial therapy for the acute manic phase, and may persist throughout treatment. Transient and mild nausea and general discomfort may also appear during the first few days of Lithium administration.
These side effects are an inconvenience rather than a disabling condition, and usually subside with continued treatment or a temporary reduction or cessation of dosage. If persistent, a cessation of dosage is indicated.
The following adverse reactions have been reported and do not appear to be directly related to serum Lithium levels.
Neuromuscular: Tremor, muscle hyperirritability (fasciculations, twitching, clonic movements of whole limbs), ataxia, choreoathetotic movements, hyperactive deep tendon reflexes.
Central Nervous System: Blackout spells, epileptiform seizures, slurred speech, dizziness, vertigo, incontinence of urine or feces, somnolence, psychomotor retardation, restlessness, confusion, stupor, coma, acute dystonia, downbeat nystagmus.
Cardiovascular: Cardiac arrhythmia, hypotension, peripheral circulatory collapse, sinus node dysfunction with severe bradycardia (which may result in syncope).
Neurological: Cases of pseudotumor cerebri (increased intracranial pressure and papilledema) have been reported with Lithium use. If undetected, this condition may result in enlargement of the blind spot, constriction of visual fields and eventual blindness due to optic atrophy. Lithium should be discontinued, if clinically possible, if this syndrome occurs.
Gastrointestinal: Anorexia, nausea, vomiting, diarrhea.
Genitourinary: Albuminuria, oliguria, polyuria, glycosuria.
Dermatologic: Drying and thinning of hair, anesthesia of skin, chronic folliculitis, xerosis cutis, alopecia and exacerbation of psoriasis.
Autonomic Nervous System: Blurred vision, dry mouth.
Thyroid Abnormalities: Euthyroid goiter and/or hypothyroidism (including myxedema) accompanied by lower T3 and T4. Iodine 131 uptake may be elevated.. Paradoxically, rare cases of hyperthyroidism have been reported.
EEG Changes: Diffuse slowing, widening of frequency spectrum, potentiation and disorganization of background rhythm.
EKG Changes: Reversible flattening, isoelectricity or inversion of T-waves.
Miscellaneous: Fatigue, lethargy, transient scotomata, dehydration, weight loss, tendency to sleep.
Miscellaneous reactions unrelated to dosage are: Transient electroencephalographic and electrocardiographic changes, leukocytosis, headache, diffuse nontoxic goiter with or without hypothyroidism, transient hyperglycemia, generalized pruritis with or without rash, cutaneous ulcers, albuminuria, worsening of or-ganic brain syndromes, excessive weight gain, edematous swelling of ankles or wrists, and thirst or polyuria, sometimes resembling diabetes insipidus, and metallic taste.
A single report has been received of the development of painful discoloration of fingers and toes and coldness of the extremities within one day of the starting of treatment of Lithium. The mechanism through which these symptoms (resembling Raynaud's Syndrome) developed is not known. Recovery followed discontinuance.
Lithium contraindications
See also:
What is the most important information I should know about Lithium?
Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation or dehydration, or sodium depletion, and to patients receiving diuretics, since the risk of Lithium toxicity is very high in such patients. If the psychiatric indication is life-threatening, and if such a patient fails to respond to other measures, Lithium treatment may be undertaken with extreme caution, including daily serum Lithium determinations and adjustment to the usually low doses ordinarily tolerated by these individuals. In such instances, hospitalization is a necessity.
Active ingredient matches for Lithium:
Lithium carbonate in Bangladesh, Belgium, Ireland, Malta, Netherlands, Oman, South Africa, Taiwan, United Kingdom.
Lithium in India.
Unit description / dosage (Manufacturer) | Price, USD |
Tablet; Oral; Lithium Carbonate | |
Eskalith cr 450 mg tablet | $ 0.80 |
Lithium Carbonate 450 mg Controlled Release Tabs | $ 0.56 |
Lithium Carbonate 300 mg Controlled Release Tabs | $ 0.50 |
Lithium Carbonate 600 mg capsule | $ 0.44 |
Lithium Carbonate 300 mg capsule | $ 0.29 |
Lithium Carbonate 300 mg tablet | $ 0.29 |
Lithate 20 mg capsule | $ 0.28 |
Lithium carb powder reagent | $ 0.27 |
Lithium carbonate 300 mg tab | $ 0.22 |
Lithium Carbonate 150 mg capsule | $ 0.21 |
Lithium Citrate 8meq/5ml Syrup | $ 0.15 |
Lithium citrate 8 meq/5 ml sol | $ 0.14 |
Pms-Lithium Carbonate 600 mg Capsule | $ 0.14 |
Carbolith 150 mg Capsule | $ 0.13 |
Lithate 5 mg capsule | $ 0.12 |
Lithane 150 mg Capsule | $ 0.11 |
Lithane 300 mg Capsule | $ 0.11 |
Carbolith 300 mg Capsule | $ 0.10 |
Apo-Lithium Carbonate 150 mg Capsule | $ 0.06 |
Apo-Lithium Carbonate 300 mg Capsule | $ 0.06 |
Pms-Lithium Carbonate 150 mg Capsule | $ 0.06 |
Pms-Lithium Carbonate 300 mg Capsule | $ 0.06 |
Lithium 300mg TAB / 10 | $ 0.22 |
Lithium 400mg SR-TAB / 10 | $ 0.34 |
300 mg x 10's | $ 0.22 |
400 mg x 10's | $ 0.34 |
Tablets; Oral; Lithium Carbonate | |
LITHIUM / MICRO SYNAPSE tab 300 mg x 10's (Micro Synapse) | $ 0.22 |
LITHIUM / MICRO SYNAPSE SR tab 400 mg x 10's (Micro Synapse) | $ 0.34 |
Lithium solution 8 meq/5mL (Roxane Laboratories, Inc (US)) | |
Lithium solution 300 mg/5mL (Precision Dose Inc. (US)) | |
List of Lithium substitutes (brand and generic names): | |
LITHITAB (India) | |
LITHITAB SR tab 400 mg x 10's (Jaiwik) | $ 0.66 |
Lithium Apogepha (Germany, Romania) | |
Lithium Capsules | |
lithium carbonate | |
Capsule; Oral; Lithium Carbonate 300 mg | |
Tablet, Extended Release; Oral; Lithium Carbonate 300 mg | |
Tablet, Extended Release; Oral; Lithium Carbonate 450 mg | |
Tablet; Oral; Lithium Carbonate 300 mg | |
Capsule; Oral; Lithium Carbonate 150 mg | |
Capsule; Oral; Lithium Carbonate 600 mg | |
100 capsule in 1 bottle, plastic | |
100 capsule in 1 box, unit-dose | |
1000 capsule in 1 bottle, plastic | |
30 capsule in 1 bottle, plastic | |
500 capsule in 1 bottle, plastic | |
Capsules; Oral; Lithium Carbonate 300 mg | |
Tablets, Extended Release; Oral; Lithium Carbonate 300 mg | |
Tablets, Extended Release; Oral; Lithium Carbonate 450 mg | |
Tablets; Oral; Lithium Carbonate 300 mg | |
Capsules; Oral; Lithium Carbonate 150 mg | |
Capsules; Oral; Lithium Carbonate 600 mg | |
Lithium Carbonate capsule, gelatin coated 150 mg/1 (West Ward Pharmaceuticals Corp (US)) | |
Lithium Carbonate capsule, gelatin coated 300 mg/1 (TYA Pharmaceuticals (US)) | |
Lithium Carbonate capsule, gelatin coated 600 mg/1 (West Ward Pharmaceuticals Corp (US)) | |
Lithium Carbonate tablet 300 mg/1 (West Ward Pharmaceuticals Corp (US)) | |
Lithium Carbonate capsule 300 mg/1 (Clinical Solutions Wholesale (US)) | |
Lithium Carbonate capsule 150 mg/1 (TYA Pharmaceuticals (US)) | |
Lithium Carbonate tablet, extended release 450 mg/1 (Major Pharmaceuticals (US)) | |
Lithium Carbonate capsule 600 mg/1 (Hetero Drugs Limited (US)) | |
Lithium Carbonate tablet, film coated, extended release 300 mg/1 (Heritage Pharmaceuticals Inc. (US)) | |
Lithium Carbonate tablet, extended release 300 mg/1 (REMEDYREPACK INC. (US)) | |
Lithium Carbonate - Alhavi (Georgia) | |
Lithium Carbonate Amel (Japan) | |
Lithium Carbonate Douglas (New Zealand) | |
Lithium Carbonate ER | |
Lithium Carbonate ER tablet 450 mg/1 (Glenmark Pharmaceuticals Inc., Usa (US)) | |
Lithium Carbonate Essential Pharma (United Kingdom) | |
Lithium carbonate Glenmark (United States) | |
Lithium Carbonate Kyowa Yakuhin (Japan) | |
Lithium Carbonate Myungin (South Korea) | |
Lithium Carbonate Nhwa (China) | |
Lithium Carbonate Roxane (United States) | |
Lithium Carbonate Yoshitomi (Japan) | |
Lithium Carbonate Zensei Yakuhin (Japan) | |
See 647 substitutes for Lithium |
Reviews
The results of a survey conducted on ndrugs.com for Lithium are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lithium. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet2 consumers reported age
Users | % | ||
---|---|---|---|
30-45 | 1 | 50.0% | |
16-29 | 1 | 50.0% |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology